10130 Federal Register / Vol. 80, No. 37 / Wednesday, February 25, 2015 / Notices 

progressive multifocal 

leukoencephalopathy (PML), and 

trichodysplasia spinulosa (TS). The 

methods could also be used to restore 

polyomavirus-specific immunity in 

immunocompromised individuals. 

Potential Commercial Applications: 

Immunotherapy for immunosuppressed 

individuals with polyomavirusassociated pathologies. 

Competitive Advantages: Methods 

allow development of polyomavirus 

antigen-specific T cells. 

Development Stage: 

• Early-stage 

• In vitro data available 

Inventors: John A. Barrett (NHLBI), 

Dhanalakshmi Chinnasamy (NHLBI), 

Pawel J. Muranski (NHLBI), Christopher 

B. Buck (NCI) 

Intellectual Property: HHS Reference 

No. E–166–2014/0—US Application No. 

62/075,726 filed November 5, 2014 

Related Technologies: 

• HHS Reference No. E–168–2011 

• HHS Reference No. E–549–2013 

Licensing Contact: Patrick McCue, 

Ph.D.; 301–435–5560; mccuepat@

od.nih.gov 

Collaborative Research Opportunity: 

The National Heart, Lung, and Blood 

Institute is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize methods to generate T 

cells responsive to multiple 

polyomaviruses. For collaboration 

opportunities, please contact Dr. 

Vincent Kolesnitchenko at kolesniv@

nhlbi.nih.gov. 

89Zr-Oxine Complex for In Vivo PET 

Imaging of Labelled Cells and 

Associated Methods 

Description of Technology: This 

technology relates to a Zirconium-89 

(89Zr)-oxine complex for cell labeling, 

tracking of labeled cells by whole-body 

positron emission tomography/

computed tomography (PET/CT) 

imaging, and associated methods. A 

long half-life of 89Zr (78.4 hours), high 

sensitivity of PET and absence of 

background signal in the recipient 

enable tracking cells over a week using 

low levels of labeling radioactivity, 

without causing cellular toxicity. The 

89Zr-oxine complex is synthesized 

quickly by mixing components at room 

temperature and produces high yields. 

Cell labeling is achieved by a short, 

room temperature incubation. The 89Zroxine complex is capable of labeling a 

wide range of cell types of therapeutic 

or pathogenic relevance (natural, 

disease, engineered cells), independent 

of factors such as cell cycle or receptor 

expression. The label is retained during 

cell division. 89Zr-oxine labeled cells 

can also be easily cross labeled (for 

example, optically or magnetically) for 

multi-modality imaging and analysis. 

Labeled cell migration and kinetics can 

be analyzed and quantified in vivo over 

a week, improving research strategies 

and ability to develop and improve cell 

therapies and diagnostics. 

Potential Commercial Applications: 

Cell therapies and diagnostics. 

Competitive Advantages: Simple 

preparation, broadly applicable cell 

label, high resolution imaging and 

monitoring over period of a week, low 

toxicity, easily combined with labeling 

technologies and cell therapies. 

Development Stage: In vivo data 

available (animal). 

Inventors: Noriko Sato (NCI), Haitao 

Wu (NHLBI), Gary L. Griffiths (NCI), 

Peter L. Choyke (NCI) 

Publications: 

1. Sato N, et al. Generation and use of 

long-lasting cell labeling agent for 

positron emission tomography (PET) 

imaging. J Nucl Med. May 2014; 55 

(Supplement 1):273. 

2. Sato N, et al. 89Zr-oxine complex 

positron emission tomography (PET) 

cell imaging for monitoring cell-based 

therapies. Radiology, 2015, In press. 

Intellectual Property: HHS Reference 

No. E–080–2014/0—US Patent 

Application No. 61/973,706 filed April 

1, 2014 

Licensing Contact: Edward (Tedd) 

Fenn; 424–297–0336; Tedd.fenn@

nih.gov 

Collaborative Research Opportunity: 

The National Cancer Institute is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate or 

commercialize cell labeling, cell 

tracking, cell trafficking, cell-based 

therapy, PET imaging. For collaboration 

opportunities, please contact John D. 

Hewes, Ph.D. at john.hewes@nih.gov or 

240–276–5515. 

Dated: February 18, 2015. 

Richard U. Rodriguez, 

Acting Director, Office of Technology 

Transfer, National Institutes of Health. 

[FR Doc. 2015–03779 Filed 2–24–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Autoimmunity Transplantation 

Intolerance. 

Date: March 11, 2015. 

Time: 3:00 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Betty Hayden, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4206, 

MSC 7812, Bethesda, MD 20892, 301–435– 

1223, haydenb@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Topics in 

Drug Discovery and Mechanisms of 

Antimicrobial Resistance. 

Date: March 13, 2015. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Guangyong Ji, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3211, 

MSC 7808, Bethesda, MD 20892, 301–435– 

1146, jig@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Skeletal 

Muscle related SBIR/STTR. 

Date: March 17, 2015. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Richard Ingraham, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4116, 

MSC 7814, Bethesda, MD 20892, 301–496– 

8551, ingrahamrh@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Program 

Project: Regulation of Cell Survival and 

Death Pathways by Fe-S Proteins. 

Date: March 19–20, 2015. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 37 / Wednesday, February 25, 2015 / Notices 10131 

1 33 CFR parts 127, 155 and 156; 46 CFR parts 10– 

15, 30–39, and 154. 

Contact Person: William A. Greenberg, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4168, 

MSC 7806, Bethesda, MD 20892, (301) 435– 

1726, greenbergwa@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 19, 2015. 

Carolyn Baum, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–03778 Filed 2–24–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2013–1084] 

Policy Letters: Guidance for the Use of 

Liquefied Natural Gas as a Marine Fuel 

AGENCY: Coast Guard, DHS. 

ACTION: Notice of availability. 

SUMMARY: On February 7, 2014, the 

Coast Guard announced the availability, 

in the docket, of two draft policy letters 

for which it sought public comment. 

This notice announces the availability 

of the finalized Coast Guard policy 

letters, including explanations of 

changes made to the policy letters and 

enclosures based on the public 

comments received. The first policy 

letter provides voluntary guidance for 

liquefied natural gas (LNG) fuel transfer 

operations on vessels using natural gas 

as fuel in U.S. waters, and training of 

personnel on those vessels. It 

recommends transfer and personnel 

training measures that we believe will 

achieve a level of safety that is at least 

equivalent to that provided for 

traditional fueled vessels. It applies to 

vessels equipped to receive LNG for use 

as fuel, but not to vessels regulated as 

LNG carriers that utilize boil-off gas as 

fuel. The second policy letter discusses 

voluntary guidance and existing 

regulations applicable to vessels and 

waterfront facilities conducting LNG 

marine fuel transfer (bunkering) 

operations. The second policy letter 

provides voluntary guidance on safety, 

security, and risk assessment measures 

we believe will enhance safe LNG 

bunkering operations. Both policy 

letters are available on the public 

docket. They have been updated to 

reflect publication numbers of the 

current year. Accordingly, as discussed 

in this notice, Policy Letter 01–14 

became Policy Letter 01–15 and Policy 

Letter 02–14 became Policy Letter 02– 

15. 

FOR FURTHER INFORMATION CONTACT: If 

you have questions on this notice, call 

or email Ken Smith, Vessel and Facility 

Operating Standards Division (CG– 

OES–2), U.S. Coast Guard; telephone 

202–372–1413, email Ken.A.Smith@

uscg.mil. If you have questions on 

viewing or submitting material to the 

docket, call Cheryl Collins, Program 

Manager, Docket Operations, telephone 

202–366–9826. 

SUPPLEMENTARY INFORMATION: 

Viewing material in the docket: To 

view the policy letters and related 

material, go to http://

www.regulations.gov, type the docket 

number (USCG–2013–1084) in the 

‘‘SEARCH’’ box and click ‘‘SEARCH.’’ 

Click on ‘‘Open Docket Folder’’ on the 

line associated with this notice. If you 

do not have access to the Internet, you 

may view the docket online by visiting 

the Docket Management facility in 

Room W12–140 on the ground floor of 

the Department of Transportation West 

Building, 1200 New Jersey Avenue SE., 

Washington, DC 20590, between 9 a.m. 

and 5 p.m., Monday through Friday, 

except Federal holidays. We have an 

agreement with the Department of 

Transportation to use the Docket 

Management Facility. 

Privacy Act: Anyone can search the 

electronic form of comments received 

into any of our dockets by the name of 

the individual submitting the comment 

(or signing the comment, if submitted 

on behalf of an association, business, 

labor union, etc.). You may review a 

Privacy Act, system of records notice 

regarding our public dockets in the 

January 17, 2008, issue of the Federal 

Register (73 FR 3316). 

Background and Purpose 

The shipping industry is exploring 

conversion from oil-based fuel to 

cleaner burning natural gas, because the 

use of natural gas as fuel would 

substantially reduce carbon emissions, 

sulfur emissions, and nitrogen oxide 

emissions. This natural gas fuel would 

be stored on and transferred to vessels 

in the form of liquefied natural gas 

(LNG). Existing regulations cover 

design, equipment, operations, and 

training of personnel on vessels that 

carry LNG as cargo and at waterfront 

facilities that handle LNG in bulk. They 

also cover conventional oil fuel transfer 

operations, but do not address LNG 

transferred as fuel.1

On February 7, 2014, the Coast Guard 

published two draft policy letters (CG– 

OES 01–14 and CG–OES 02–14), 

requesting comments, that 

recommended the transfer procedures 

and other operating guidelines for 

vessels and waterfront facilities 

providing LNG to vessels for use as fuel 

and for vessels operating in U.S. waters 

that will be fueled with natural gas that 

will be stored onboard as LNG. The 

Coast Guard has revised these policy 

letters based on comments received and 

now makes the final policy letters 

available to the public. 

The policy letters and voluntary 

guidance do not apply to vessels 

regulated as LNG carriers that utilize 

their boil-off gas as fuel. They also do 

not provide guidance on vessel design 

criteria for natural gas fuel systems or 

design of vessels providing LNG for use 

as fuel. If you have questions about the 

design of these systems, please contact 

the Coast Guard’s Office of Design and 

Engineering Standards (CG–ENG, 

formerly CG–521). See FOR FURTHER

INFORMATION CONTACT section for contact 

information. 

Discussion 

The Coast Guard received 27 letters 

from the public containing a combined 

total of 185 individual comments which 

are discussed below. We discuss more 

fully the changes we made to the policy 

letters in response to comments. 

All letters received were generally 

supportive of the Coast Guard’s effort to 

provide guidance on the use and 

transfer of LNG as a marine fuel and the 

Coast Guard appreciates this important 

feedback. 

We also received various comments 

recommending changes that cannot be 

made in a policy document because the 

Coast Guard would need to undergo 

rulemaking to make these recommended 

changes enforceable. For example, one 

submitter suggested that we provide 

specific details concerning the 

information that risk assessments 

should contain. Another submitter 

suggested that we provide common 

checklists for industry to follow when 

conducting bunkering operations. The 

Coast Guard will consider these 

comments and determine whether any 

further action is necessary. 

Additionally, the Coast Guard received 

comments on matters unrelated to the 

two policy letters discussed in this 

notice. Those comments have been 

reviewed but did not effect any changes 

to these policy letters. Examples of some 

of the comments we received pertaining 

to design were related to venting 

arrangements, LNG tank design, and gas 

detection. 


asabaliauskas on DSK5VPTVN1PROD with NOTICES